Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	Oliena Studio Stroke and language recovery: 9000+ videos Español • Italiano • Sardu • English | PDF+

Autoimmune Disorders

Free Subscription 29.07.2019 1 BMC Neurol 1 Brain 4 Diabetes Res Clin Pract 1 J Autoimmun 1 J Immunol 1 J Neurol 1 Lancet Diabetes Endocrinol 17 Mult Scler 1 N Engl J Med 1 Nat Rev Neurol 1 Neurol Clin Pract 7 Neurology

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

BMC Neurol

1. KLEHMET J, Beutner S, Hoffmann S, Dornauer M, et al
   Quantitative grip force assessment of muscular weakness in chronic inflammatory demyelinating polyneuropathy.
   BMC Neurol. 2019;19:118.
   PubMed     Text format     Abstract available
   
   

   
   Brain

2. BROWNLEE WJ, Altmann DR, Prados F, Miszkiel KA, et al
   Early imaging predictors of long-term outcomes in relapse-onset multiple sclerosis.
   Brain. 2019;142:2276-2287.
   PubMed     Text format     Abstract available
   
   

   
   Diabetes Res Clin Pract

3. ELBARBARY N, Deeb A, Habeb A, Beshyah SA, et al
   Management of diabetes during Ramadan fasting in children and adolescents: A survey of physicians' perceptions and practices in the Arab Society for Paediatric Endocrinology and Diabetes (ASPED) countries.
   Diabetes Res Clin Pract. 2019;150:274-281.
   PubMed     Text format     Abstract available
   
   
4. BASHIER AMK, Hussain AKB, Alawadi F, Alsayyah F, et al
   Impact of optimum diabetes care on the safety of fasting in Ramadan in adult patients with type 2 diabetes mellitus on insulin therapy.
   Diabetes Res Clin Pract. 2019;150:301-307.
   PubMed     Text format     Abstract available
   
   
5. PRIKKEN S, Raymaekers K, Oris L, Rassart J, et al
   A triadic perspective on control perceptions in youth with type 1 diabetes and their parents: Associations with treatment adherence and glycemic control.
   Diabetes Res Clin Pract. 2019;150:264-273.
   PubMed     Text format     Abstract available
   
   
6. CLEAL B, Willaing I, Stuckey H, Peyrot M, et al
   Work matters: Diabetes and worklife in the second diabetes attitudes, wishes and needs (DAWN2) study.
   Diabetes Res Clin Pract. 2019;150:90-98.
   PubMed     Text format     Abstract available
   
   

   
   J Autoimmun

7. KOLB H, Burkart V
   Chaperones may cause the focus of diabetes autoimmunity on distinct (pro)insulin peptides.
   J Autoimmun. 2019 Jul 18:102304. doi: 10.1016/j.jaut.2019.102304.
   PubMed     Text format     Abstract available
   
   

   
   J Immunol

8. ZHANG X, Kiapour N, Kapoor S, Khan T, et al
   IL-11 Induces Encephalitogenic Th17 Cells in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis.
   J Immunol. 2019 Jul 24. pii: jimmunol.1900311. doi: 10.4049/jimmunol.1900311.
   PubMed     Text format     Abstract available
   
   

   
   J Neurol

9. KIMURA K, Okada Y, Fujii C, Komatsu K, et al
   Clinical characteristics of autoimmune disorders in the central nervous system associated with myasthenia gravis.
   J Neurol. 2019 Jul 24. pii: 10.1007/s00415-019-09461.
   PubMed     Text format     Abstract available
   
   

   
   Lancet Diabetes Endocrinol

10. MORGAN J
    Craig Stubing: the art of managing type 1 diabetes.
    Lancet Diabetes Endocrinol. 2018 Aug 21. pii: S2213-8587(18)30261.
    PubMed     Text format    
    
    

    
    Mult Scler

11. CALLESEN J, Cattaneo D, Brincks J, Kjeldgaard Jorgensen ML, et al
    How do resistance training and balance and motor control training affect gait performance and fatigue impact in people with multiple sclerosis? A randomized controlled multi-center study.
    Mult Scler. 2019 Jul 24:1352458519865740. doi: 10.1177/1352458519865740.
    PubMed     Text format     Abstract available
    
    
12. ZECCA C, Merlini A, Disanto G, Rodegher M, et al
    Half-dose fingolimod for treating relapsing-remitting multiple sclerosis: Observational study.
    Mult Scler. 2017 Feb 1:1352458517694089. doi: 10.1177/1352458517694089.
    PubMed     Text format     Abstract available
    
    
13. WESNES K, Myhr KM, Riise T, Cortese M, et al
    Physical activity is associated with a decreased multiple sclerosis risk: The EnvIMS study.
    Mult Scler. 2017 Feb 1:1352458517694088. doi: 10.1177/1352458517694088.
    PubMed     Text format     Abstract available
    
    
14. PATEL VP, Walker LA, Feinstein A
    Revisiting cognitive reserve and cognition in multiple sclerosis: A closer look at depression.
    Mult Scler. 2017 Feb 1:1352458517692887. doi: 10.1177/1352458517692887.
    PubMed     Text format     Abstract available
    
    
15. SONNENBERG A, Ajdacic-Gross V
    Similar birth-cohort patterns in Crohn's disease and multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517691620. doi: 10.1177/1352458517691620.
    PubMed     Text format     Abstract available
    
    
16. DE STEFANO N, Giorgio A, Battaglini M, De Leucio A, et al
    Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets.
    Mult Scler. 2017 Jan 1:1352458517690269. doi: 10.1177/1352458517690269.
    PubMed     Text format     Abstract available
    
    
17. MOTL RW, Mowry EM, Ehde DM, LaRocca NG, et al
    Wellness and multiple sclerosis: The National MS Society establishes a Wellness Research Working Group and research priorities.
    Mult Scler. 2017 Jan 1:1352458516687404. doi: 10.1177/1352458516687404.
    PubMed     Text format     Abstract available
    
    
18. BRIGGS FB, Hill E
    Estimating the prevalence of multiple sclerosis using 56.6 million electronic health records from the United States.
    Mult Scler. 2019 Jul 24:1352458519864681. doi: 10.1177/1352458519864681.
    PubMed     Text format     Abstract available
    
    
19. CACAO G, Santos E, Martins Silva A
    Concurrent autoimmune hepatitis in multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517692885. doi: 10.1177/1352458517692885.
    PubMed     Text format     Abstract available
    
    
20. SCHWARTZ CE, Grover SA, Powell VE, Noguera A, et al
    Risk factors for non-adherence to disease-modifying therapy in pediatric multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517695469. doi: 10.1177/1352458517695469.
    PubMed     Text format     Abstract available
    
    
21. ROY S, Drake AS, Eizaguirre MB, Zivadinov R, et al
    Trait neuroticism, extraversion, and conscientiousness in multiple sclerosis: Link to cognitive impairment?
    Mult Scler. 2017 Feb 1:1352458517695467. doi: 10.1177/1352458517695467.
    PubMed     Text format     Abstract available
    
    
22. MAILLEUX J, Vanmierlo T, Bogie JF, Wouters E, et al
    Active liver X receptor signaling in phagocytes in multiple sclerosis lesions.
    Mult Scler. 2017 Feb 1:1352458517696595. doi: 10.1177/1352458517696595.
    PubMed     Text format     Abstract available
    
    
23. GIACOMINI E, Rizzo F, Etna MP, Cruciani M, et al
    Thymosin-alpha1 expands deficient IL-10-producing regulatory B cell subsets in relapsing-remitting multiple sclerosis patients.
    Mult Scler. 2017 Feb 1:1352458517695892. doi: 10.1177/1352458517695892.
    PubMed     Text format     Abstract available
    
    
24. CORIC D, Balk LJ, Verrijp M, Eijlers A, et al
    Cognitive impairment in patients with multiple sclerosis is associated with atrophy of the inner retinal layers.
    Mult Scler. 2017 Feb 1:1352458517694090. doi: 10.1177/1352458517694090.
    PubMed     Text format     Abstract available
    
    
25. BOGIE JF, Boelen E, Louagie E, Delputte P, et al
    CD169 is a marker for highly pathogenic phagocytes in multiple sclerosis.
    Mult Scler. 2017 Mar 1:1352458517698759. doi: 10.1177/1352458517698759.
    PubMed     Text format     Abstract available
    
    
26. CORTESE M, Riise T, Bjornevik K, Myhr KM, et al
    Body size and physical exercise, and the risk of multiple sclerosis.
    Mult Scler. 2017 Mar 1:1352458517699289. doi: 10.1177/1352458517699289.
    PubMed     Text format     Abstract available
    
    
27. RIO J, Rovira A, Tintore M, Otero-Romero S, et al
    Disability progression markers over 6-12 years in interferon-beta-treated multiple sclerosis patients.
    Mult Scler. 2017 Mar 1:1352458517698052. doi: 10.1177/1352458517698052.
    PubMed     Text format     Abstract available
    
    

    
    N Engl J Med

28. FREEMAN MW, Singh AK, Guidon AC, Arvikar SL, et al
    Case 22-2019: A 65-Year-Old Woman with Weakness, Dark Urine, and Dysphagia.
    N Engl J Med. 2019;381:275-283.
    PubMed     Text format    
    
    

    
    Nat Rev Neurol

29. FYFE I
    Multiple sclerosis: Stem cell treatment suppresses multiple sclerosis in the long term.
    Nat Rev Neurol. 2017 Mar 10. doi: 10.1038/nrneurol.2017.
    PubMed     Text format    
    
    

    
    Neurol Clin Pract

30. TYSHKOV C, Pawate S, Bradshaw MJ, Kimbrough DJ, et al
    Multiple sclerosis and sarcoidosis: A case for coexistence.
    Neurol Clin Pract. 2019;9:218-227.
    PubMed     Text format     Abstract available
    
    

    
    Neurology

31. PATIL A, Shree R, Naheed D, Goyal MK, et al
    Pearls & Oy-sters: Paraneoplastic cerebral vasculitis: Rare cause of spontaneous convexity subarachnoid hemorrhage.
    Neurology. 2018;90:e815-e817.
    PubMed     Text format    
    
    
32. SALVARANI C, Brown RD Jr, Christianson TJH, Huston J 3rd, et al
    Primary central nervous system vasculitis associated with lymphoma.
    Neurology. 2018 Feb 2. pii: WNL.0000000000005062.
    PubMed     Text format     Abstract available
    
    
33. ALGAEED M
    Author response: Pearls & Oy-sters: Pembrolizumab-induced myasthenia gravis.
    Neurology. 2019;93:184.
    PubMed     Text format    
    
    
34. ROBBINS NM, Mozaffar T, Mammen AL, Liewluck T, et al
    Reader response: Pearls & Oy-sters: Pembrolizumab-induced myasthenia gravis.
    Neurology. 2019;93:183-184.
    PubMed     Text format    
    
    
35. GANESH A, Galetta S
    Editors' note: Pearls & Oy-sters: Pembrolizumab-induced myasthenia gravis.
    Neurology. 2019;93:182-183.
    PubMed     Text format    
    
    
36. MATEEN FJ
    Multiple sclerosis in resource-limited settings: Research opportunities in an unequal world.
    Neurology. 2019;93:176-180.
    PubMed     Text format     Abstract available
    
    
37. DE GIGLIO L, De Luca F, Gurreri F, Ferrante I, et al
    Effect of dalfampridine on information processing speed impairment in multiple sclerosis.
    Neurology. 2019 Jul 22. pii: WNL.0000000000007970.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Autoimmune Disorders is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: